Disc Medicine
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeu...
Latest News
12 days ago · globenewswire.com
Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business UpdateWATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a review of recent program and corporate developments.
15 days ago · globenewswire.com
Disc Medicine to Participate in Upcoming Investor ConferencesWATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that company management will participate in fireside chats at upcoming investor conferences:
27 days ago · globenewswire.com
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common StockWATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an upsized underwritten public offering of shares of its common stock. Disc is selling 6,000,000 shares of common stock at a public offering price of $75.00 per share. In addition, Disc has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The aggregate gross proceeds to Disc from this offering are expected to be $450 million, before deducting underwriting discounts and commissions and other offering expenses, assuming no exercise of the underwriters' option to purchase additional shares. The offering is expected to close on October 22, 2026, subject to the satisfaction of customary closing conditions.
28 days ago · globenewswire.com
Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded WarrantsWATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the commencement of an underwritten public offering of $350 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock.
28 days ago · seekingalpha.com
Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP TranscriptDisc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP Transcript
29 days ago · benzinga.com
Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal StudyDisc Medicine Inc. (NASDAQ:IRON) on Monday reported positive topline results from its APOLLO Phase 3 trial evaluating bitopertin for erythropoietic protoporphyria, or EPP, including X-linked protoporphyria, or XLP.
29 days ago · invezz.com
Disc Medicine stock soars: take profit or buy into strength?Disc Medicine (IRON) shares ripped higher on Monday morning after the company's experimental blood-disorder treatment, bitopertin, delivered positive Phase 3 results. In its press release, management said the APOLLO clinical trial met every primary and secondary endpoint, strengthening the firm's case for another FDA submission.
29 days ago · gurufocus.com
Disc Medicine (IRON) Achieves Positive Phase 3 Trial Results for EPP TreatmentDisc Medicine (IRON) is experiencing a significant surge today following the announcement of positive results from its pivotal Phase 3 APOLLO trial for bitopert
29 days ago · marketbeat.com
Disc Medicine's Bitopertin Nails Phase III Endpoints, Eyes FDA ResubmissionDisc Medicine NASDAQ: IRON said its Phase III APOLLO trial of investigational bitopertin met both co-primary endpoints and all secondary endpoints in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), supporting the company's plan to resubmit a new drug application to the U.S. Food and Drug Administration by the end of the year.
29 days ago · barrons.com
Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval HopesDisc Medicine plans to resubmit its blood-disorder drug for FDA approval by year-end after a late-stage trial met all its primary and secondary goals.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove IRON